Quotient Evidence white paper discusses the role of biomarkers in metabolic syndrome

Quotient Evidence white paper discusses the role of biomarkers in metabolic syndrome

23 December 2009, Fordham, Cambridgeshire, UK: Quotient Bioresearch has added to its ongoing ‘Evidence’ information programme with a new white paper now available for download at: www.quotientbioresearch.com/news. Biomarkers in Metabolic Syndrome - Cardiovascular Disease and Type 2 Diabetes explores the multifaceted relationship between metabolic syndrome and the increased risk of developing cardiovascular disease (CVD) and type 2 diabetes mellitus (T2D). The white paper highlights how biomarkers of CVD and T2D can add value to drug discovery and development in this important therapeutic area.

David Griffiths, Business Development Director, Quotient Bioresearch commented: “The mechanisms and pathways of metabolic syndrome are not completely known and, although it is generally agreed that weight, genetics, age, and lifestyle are important factors leading to metabolic syndrome, the pathophysiology is intricate and its cause remains elusive. We have seen the role for biomarkers increase dramatically as companies look to understand the complex pathways leading to CVD and T2D. Quotient’s expertise in developing relevant strategies and using novel techniques for marker measurement is making an important contribution to clients active in this challenging research.”

Metabolic syndrome is a cluster of disorders that increases the risk of developing CVD and T2D. It is thought to affect approximately 1 in 5 people, with some studies estimating the prevalence in the USA and Europe as high as 25%.

Quotient’s ‘Evidence’ white paper programme is one of a series of e-news items that regularly reviews the company’s scientific research and therapeutic capability. To request a copy of the whitepaper, and for more details about Quotient Bioresearch and the company’s unique range of drug development services please Contact Us.

Download Press Release